With around twenty scientific contributions, the center reaffirms its commitment to translational research and innovation in oncology.
The 4CB teams have contributed with oral communications, rapid abstracts, posters, and educational sessions in areas such as breast, lung, melanoma, glioblastoma, prostate, liver, bladder, and digestive tumors. These contributions demonstrate a clear commitment to integrating genomic biomarkers, immunotherapy, targeted therapies, nuclear medicine, and therapeutic de-escalation strategies.
Among the highlights is the clinical validation of the HER2DX test, developed by the Campus Clínic spin-off Reveal Genomics. This is an oral presentation of the U.S. CompassHER2-pCR study, led by ECOG-ACRIN and funded by the National Cancer Institute (NCI). In more than 560 patients with HER2+ breast cancer, HER2DX enabled the identification of tumors with a high probability of complete response to a regimen without anthracyclines, consolidating itself as a key tool for personalizing and de-escalating treatment. This work is part of a set of four independent international studies, with more than 800 patients, that consolidate the clinical utility of HER2DX in different scenarios.
Additionally, Dr. Maria José Ribal, head of the 4CB Uro-Oncology Unit, will participate in an educational session on perioperative treatment of muscle-invasive bladder cancer, focusing on the universal use of immunotherapy or risk-adapted approaches. Dr. Francesc Balaguer, head of the Gastroenterology Service, will co-chair an educational session on pharmacological strategies for cancer risk reduction, where he will also give a talk focused on digestive tumors. Finally, Dr. Ana Arance, medical oncologist at 4CB, will take part in an oral session on advanced melanoma, highlighting the role of Clínic-IDIBAPS in immunotherapy research.
“The active participation of our center at ASCO 2025 is a clear demonstration of scientific ambition, commitment to quality research, and the international impact of 4CB,” states Dr. Aleix Prat, director of the Clínic Barcelona Comprehensive Cancer Center.
Dr. Elias Campo, research director of 4CB, adds, “These presentations reflect the cross-cutting nature of our projects and the high capacity of our teams to generate relevant knowledge that transforms clinical practice.”
A model of international excellence
The Clínic Barcelona Comprehensive Cancer Center, under the direction of Dr. Aleix Prat, represents a new model of excellence that integrates care, research, and training under one umbrella. This multidisciplinary structure guarantees personalized care and rapid access to innovations, positioning the center as a national and international reference in oncology.
The heart of the center: innovation, research, and multidisciplinary care
4CB organizes its care and research activity through multidisciplinary functional units, integrating specialists from all areas involved in the diagnosis and treatment of cancer. These units ensure comprehensive and personalized care and promote the incorporation of research and teaching into daily clinical practice.
The center also has transversal areas of great strategic value, such as the Oncoimmunology Unit, the Hereditary Cancer Program, or the Molecular Tumor Committee, which drive precision medicine.
With 25 high-impact research groups and its own clinical trials unit in onco-hematology, 4CB strengthens its commitment to innovation and access to advanced treatments for patients.
